- Holloway, K. and T. Green, Drug and therapeutics committees: a practical guide, in Drug and therapeutics
committees: a practical guide. 2003. p. 146-146.
2. Phillips, M.S., J.E. Gayman, and M.W. Todd, ASHP guidelines on medication-use evaluation. American
Society of Health-system Pharmacists. American Journal of Health-System Pharmacy, 1996. 53(16): p. 1953-
1955.
3. Fanikos, J., et al., Medication use evaluation: pharmacist rubric for performance improvement.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014. 34(S1): p. 5S-13S.
4. Organization, W.H. and W.H.O. WHO, Drug and therapeutics committees: a practical guide Department of
Essential Drugs and Medicines Policy. Managing the formulary process. Geneva: WHO, 2003.
5. Shahbazi, F. and S. Dashti-Khavidaki, Colistin: efficacy and safety in different populations. Expert review of
clinical pharmacology, 2015. 8(4): p. 423-448.
6. Dantas, R.C., et al., Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of
resistance on outcome. Journal of medical microbiology, 2014. 63(12): p. 1679-1687.
7. Mauldin, P.D., et al., Attributable hospital cost and length of stay associated with health care-associated
infections caused by antibiotic-resistant gram-negative bacteria. Antimicrobial agents and chemotherapy,
2010. 54(1): p. 109-115.
8. Kim, B.-N., et al., Management of meningitis due to antibiotic-resistant Acinetobacter species. The Lancet
infectious diseases, 2009. 9(4): p. 245-255.
9. Paterson, D.L., Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic
therapy. Clinical infectious diseases, 2008. 47(Supplement_1): p. S14-S20.
- 10. Bargiacchi, O., et al., Intrathecal/intraventricular colistin in external ventricular device-related infections by
multi-drug resistant Gram negative bacteria: case reports and review. Infection, 2014. 42(5): p. 801-809.
11. Betrosian, A.P., et al., Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for
the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Journal of
Infection, 2008. 56(6): p. 432-436.
12. Cprek, J.B. and J.C. Gallagher, Ertapenem-containing double-carbapenem therapy for treatment of infections
caused by carbapenem-resistant Klebsiella pneumoniae. Antimicrobial agents and chemotherapy, 2016. 60(1):
p. 669-673.
13. Rezaie, N., et al., Colistin Utilization Evaluation in a Major Teaching Hospital in Iran. Journal of
Pharmaceutical Care, 2018. 6(1-2): p. 19-22.
14. Vazin, A., et al., Evaluating adherence of health-care team to standard guideline of colistin use at intensive
care units of a referral hospital in Shiraz, Southwest of Iran. Advanced pharmaceutical bulletin, 2017. 7(3): p.
391.
15. Shoaei, S., et al., Vancomycin and five broad-spectrum antibiotic utilization evaluation in an educational
medical center in one year. Journal of Pharmaceutical Care, 2014: p. 154-161.
16. Rafati, M.R., et al., Antibiotics Usage in Intensive Care Unit in Sari Bouali Sina Hospital. Journal of
Mazandaran University of Medical Sciences, 2015. 24(122): p. 12-21.
17. Khoshdel, A. and G. Panahandeh, The pattern of antimicrobial utilization in patients of pediatric wards in
Hajar hospital, Shahrekord, Iran in 2009-2010. Journal of Shahrekord Uuniversity of Medical Sciences, 2012.
14(5): p. 54-62.
18. Ozkurt, Z., et al., Changes in antibiotic use, cost and consumption after an antibiotic restriction policy applied
by infectious disease specialists. Japanese journal of infectious diseases, 2005. 58(6): p. 338.
19. Makris, D., et al., Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter
baumannii ventilator-associated pneumonia treatment: An open-label prospective study. Indian journal of
critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine, 2018.
22(2): p. 67.
20. Lim L.M., Ly N., et al., Resurgence of Colistin: A Review of Resistance, Toxicity. Pharmacodynamics, and
Dosing, Pharmacotherapy, 2010 Dec; 30(12):1279-91.
21. Iosifidis, E., et al., Colistin administration to pediatric and neonatal patients. European Journal of Pediatrics,
2010. 169(7): p. 867-874.
22. Garonzik, S., et al., Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically
ill patients from a multicenter study provide dosing suggestions for various categories of patients.
Antimicrobial agents and chemotherapy, 2011. 55(7): p. 3284-3294.
23. Spapen, H., et al., Renal and neurological side effects of colistin in critically ill patients. Annals of intensive
care, 2011. 1(1): p. 14.
24. Sabuda, D.M., et al., Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa.
Canadian Journal of Infectious Diseases and Medical Microbiology, 2008. 19(6): p. 413-418.
25. Reed, M.D., et al., The pharmacokinetics of colistin in patients with cystic fibrosis. The Journal of Clinical
Pharmacology, 2001. 41(6): p. 645-654.
26. Gilbert, B. and C. Morrison, Evaluation of intraventricular colistin utilization: A case series. Journal of critical
care, 2017. 40: p. 161-163.
27. Pestotnik, S.L., et al., Implementing antibiotic practice guidelines through computer-assisted decision support:
clinical and financial outcomes. Annals of internal medicine, 1996. 124(10): p. 884-890.
|
